公司简介

CellCentric is a biotechnology company that targets at deubiquitinase (DUB) enzyme for cancer therapy.

主要成员

Will West、Neil Pegg、Thea Stanway 、Nigel Brooks、Karen Clegg、Jason Dinges

产品/服务

• 药物基因组

first-in-class small molecule p300/CBP inhibitors

for the treatment of late stage prostate and other cancers.

融资信息

融资轮次	融资日期	投资方	融资额度
Venture Round	2013-06	Providence Investment Company Limited、Morningside Venture Capital、UK Innovation & Science Seed Fund	£4.3M
Venture Round	2017-06	Nesta Ventures	未披露
Venture Round	2018-05	Morningside Venture	$26M

关联公司